A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Halia Therapeutics awarded Novo Nordisk Golden Ticket to advance obesity and inflammation research: Lehi, Utah Thursday, March 13, 2025, 13:00 Hrs [IST] Halia Therapeutics, a clin ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...